Related Experiment Videos
Development of a quantitative vancomycin immunoassay for the Abbott AxSYM analyzer
M Adamczyk1, E M Brate, E G Chiappetta
1Abbott Diagnostics Division, Abbott Laboratories, Abbott Park, Illinois 60064, USA.
Therapeutic Drug Monitoring
|April 29, 1998
Summary
A new fluorescence polarization immunoassay accurately measures vancomycin levels, even with its degradation product present. This method offers reliable quantification for vancomycin drug monitoring.
Area of Science:
- Clinical Chemistry
- Immunoassay Development
- Pharmacokinetics
Background:
- Accurate vancomycin monitoring is crucial for therapeutic efficacy and patient safety.
- Existing assays may face interference from vancomycin's crystalline degradation product (CDP).
Purpose of the Study:
- To develop and validate a novel fluorescence polarization immunoassay (FPIA) for vancomycin quantification.
- To assess the assay's performance in the presence of CDP and other potential interferents.
Main Methods:
- Development of a fluorescence polarization immunoassay for vancomycin.
- Validation on the Abbott AxSYM analyzer.
- Testing for linearity, precision, recovery, sensitivity, and cross-reactivity.
Main Results:
- The FPIA demonstrated accurate vancomycin quantification, unaffected by CDP.
- Assay performance included dilution linearity (1.0–100.0 µg/mL), low coefficients of variation (2.94–4.26%), high recovery (98–105%), and sensitivity (<2.0 µg/mL).
- No cross-reactivity was observed with CDP, common drugs, or significant interference from endogenous substances.
Conclusions:
- The novel FPIA provides a robust and specific method for vancomycin measurement.
- This assay is suitable for routine therapeutic drug monitoring, ensuring reliable vancomycin level assessment.